Phase 1b Study of Autologous CD22 CAR T Cell Therapy for Adults with Recurrent or Resistant B Cell Lymphomas

What this Trial Is About

Researchers are evaluating the safety and effectiveness of CD22CART therapy in adults with relapsed or refractory B Cell Lymphomas, including Follicular Lymphoma, Mantle Cell Lymphoma, and other related lymphomas. This non-randomized Phase 1 trial monitors participants who complete leukapheresis, lymphodepleting chemotherapy, and CD22CART infusion for overall survival, progression-free survival, and duration of response. Participants will receive CD22CART after undergoing lymphodepleting chemotherapy. The treatment involves hospitalization for approximately 5 to 7 days during CD22CART infusion, with discharge possible once adverse events have reduced to a mild level or as decided by the physician. Four cohorts are included based on lymphoma type, each receiving recommended doses of CD22CART. Throughout the study, participants will be closely monitored with regular assessments of their disease status, safety, and response to treatment over multiple years. Researchers will measure primary outcomes such as manufacturing feasibility and overall response rates, as well as secondary outcomes including progression-free survival and duration of response. The total study duration spans up to six years with ongoing follow-up.

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas